Psilocybin rTMS for Treatment Resistant Depression
NCT06132178
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Treatment Resistant Depression
- MDD
- Major Depressive Disorder
- Recurrent Depression
- Depression
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 22 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Texas at Austin
- Last updated on ClinicalTrials.gov
- November 26, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600 · Austin, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.